Combined molecular targets

The term 'Combined molecular targets' does not refer to a single, specific biological entity such as a protein, enzyme, or receptor. Instead, it is a conceptual or descriptive phrase used in pharmacology to denote the simultaneous targeting of multiple distinct molecular entities to achieve a synergistic therapeutic effect or to overcome drug resistance (PubMed, 2015; MDPI, 2023). This approach is common in treating complex diseases like cancer, sepsis, and viral infections, where single-target inhibition may be insufficient due to pathway redundancy or compensatory mechanisms (PubMed, 2015; Journal of Medicinal Chemistry, 2017). For example, multi-target agents are designed to downregulate several proteins simultaneously, such as the c-MET, STAT3, and AKT signaling axis, to suppress cancer cell survival and drug resistance (MDPI, 2023; PMC, 2023). Because it is a collective designation rather than a unique biochemical target, it lacks a specific molecular classification, biological function, or localized disease role (R Discovery, 2023). In structured pharmacological data, this entry is considered incorrect or non-specific, as it encompasses a broad range of potential target combinations rather than a defined therapeutic target (PubMed, 2015; R Discovery, 2023). The use of multi-target strategies aims to improve clinical outcomes by addressing the multifaceted nature of disease pathology through the modulation of diverse biological pathways.

Other names

Multi-target therapeuticsPolypharmacological targetsCombination therapy targetsMultiple molecular targets

Not applicable